Core Viewpoint - Aesthetic Medical International Holdings Group Limited has received approval from the Nasdaq Hearings Panel to continue its listing, contingent upon certain conditions being met by specified deadlines [1][2]. Group 1: Nasdaq Listing Status - The Company was notified on March 6, 2024, that it had not regained compliance with the Minimum Bid Price Rule within the 180-day grace period and is not eligible for a second grace period [2]. - Following a hearing on April 11, 2024, the Panel decided on April 22, 2024, to grant the Company's request for continued listing, subject to conditions including board approval for a reverse stock split at a 10-for-1 ratio by May 15, 2024, and demonstrating compliance with the Minimum Bid Price Rule by September 3, 2024 [1][2]. Group 2: Company Overview - Aesthetic Medical International Holdings Group Limited, known as "Peng'ai" in China, is a leading provider of aesthetic medical services, operating treatment centers across major cities in mainland China, particularly in the Guangdong-Hong Kong-Macau Greater Bay area and the Yangtze River Delta area [3]. - The Company offers a comprehensive range of aesthetic services, including surgical and non-surgical treatments, general medical services, and other aesthetic offerings, leveraging over 20 years of clinical experience [3].
Aesthetic Medical International Holdings Group Ltd. Announces Receipt of Decision from the Nasdaq Hearings Panel for Conditional Continued Listing